Skip to main content
Medios AG logo

Medios AG — Investor Relations & Filings

Ticker · ILM1 ISIN · DE000A1MMCC8 LEI · 391200Z7Z09IHDBT2L23 F Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2021-01-22 Declaration of Voting R…
Country DE Germany
Listing F ILM1

About Medios AG

https://medios.ag/en/

Medios AG is a specialty pharmaceutical company focused on providing solutions for complex and rare diseases. The company's core business encompasses two main segments: the wholesale distribution of specialty pharma drugs and the manufacturing of patient-specific therapies. The manufacturing division compounds personalized medications, such as sterile infusions, for individual patients. As a comprehensive partner, Medios covers critical aspects of the supply chain for specialized pharmacies, medical practitioners, and pharmaceutical companies. The company is also dedicated to advancing individualized medicine by pioneering biotechnological precision medicine and advanced therapies to provide patients with innovative treatments.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports changes in the percentage of voting rights held by an individual (Manfred Schneider) and associated entities, crossing specific thresholds. This directly corresponds to the definition of a notification of changes in significant share ownership levels, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a specific disclosure of shareholding changes, not the results of a vote (DVA).
2021-01-22 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement titled 'Total Voting Rights Announcement' from Medios AG, dated January 21, 2021. It explicitly mentions compliance with Article 41 of the WpHG (German Securities Trading Act) and details the 'Publication of total number of voting rights' and notes an 'Other capital measure'. This type of regulatory disclosure regarding the total number of shares/voting rights is a specific corporate action notification. While it relates to capital structure, it is not a general financing update (CAP) or a share issue/repurchase (SHA/POS). It is a specific regulatory disclosure concerning voting rights, which fits best under the general regulatory announcement category, RNS, as it is a mandatory disclosure under German law that doesn't fit the other specific categories like DVA (which is for *results* of a vote) or SHA (which is for the *action* of issuing shares, not just reporting the total count). Given the nature of mandatory regulatory disclosure via DGAP/EQS, RNS is the most appropriate fallback/general regulatory code.
2021-01-21 English
Medios AG: Successful completion of the Cranach Pharma acquisition - Market position strengthened significantly
M&A Activity Classification · 100% confidence The document is a press release announcing the successful completion of an acquisition (Medios AG taking over Cranach Pharma GmbH). It details the terms of the transaction, including the use of new shares as payment (a capital increase in kind), the resulting change in share capital, and the expected impact on sales. This type of announcement, detailing a significant corporate transaction like a merger or takeover, directly corresponds to the M&A Activity category. The keywords 'takeover', 'acquisition', 'merger proposals', and 'purchase price' strongly indicate the 'TAR' (M&A Activity) filing type. It is not a formal regulatory report like a 10-K or IR, but a specific corporate action announcement.
2021-01-21 English
Medios AG: Planned takeover of Cranach Pharma GmbH approved by Cartel Office
Regulatory Filings Classification · 99% confidence The document is a short press release dated December 21, 2020, announcing that the German Federal Cartel Office has approved Medios AG's planned takeover of Cranach Pharma GmbH. This announcement concerns a significant corporate transaction (merger/acquisition). Based on the provided definitions, the most appropriate category for an announcement related to a merger proposal or takeover bid is 'M&A Activity' (Code: TAR). Although it is a news release, the specific subject matter (takeover approval) makes TAR more precise than the general 'RNS' fallback.
2020-12-21 English
Report Publication Announcement 2020
Report Publication Announcement Classification · 100% confidence The document is titled "Medios AG: Preliminary announcement of the publication of financial reports..." and explicitly states that it is a 'Preliminary announcement of the publication of financial reports'. It lists future disclosure dates for various reports (Annual financial report, Group financial report, Half-year/Q2 report) along with links, but it does not contain the content of those reports. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement detailing the publication of other reports classifies as a Report Publication Announcement (RPA).
2020-11-27 English
Medios AG: Sales increase to more than 1 billion through acquisition of Cranach Pharma GmbH
M&A Activity Classification · 99% confidence The document is a press release dated November 26, 2020, announcing that Medios AG has concluded a purchase agreement to acquire Cranach Pharma GmbH. The key focus is on the strategic implications of this acquisition, including expected increases in sales (to over €1 billion) and EBITDA, and the financing method (issuance of new shares). This content directly relates to corporate actions involving financing, capital structure changes, and potentially M&A activity. Since the document details the acquisition terms and the resulting capital increase (issuance of 4,180,000 new shares), it strongly aligns with 'Capital/Financing Update' (CAP) due to the explicit discussion of share issuance as consideration. While it involves a takeover (TAR), the primary focus of the announcement's financial impact centers on the capital structure change and fundraising aspect. Given the explicit mention of issuing new shares as consideration, CAP is the most precise fit over TAR, which usually covers the bid/proposal itself. It is not a standard regulatory filing like 10-K or ER, but a specific corporate action announcement.
2020-11-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.